Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers

被引：0
|
作者：
Hsieh, Yi-Lin [1 ]
Yu, Pei-Ning [1 ]
Jan, Yi-Hua [1 ]
Lai, Meng-Shao [1 ]
Wang, Woei-Fuh [1 ]
Zhuo, De-Wei [1 ]
Chen, Shu-Jen [1 ]
Cheng, Jen-Hao [1 ]
Tan, Kien Thiam [1 ]
Su, Yu-Li [2 ]
机构：
[1] ACT Genom, Taipei, Taiwan
[2] Chang Gung Mem Hosp, Kaohsiung, Taiwan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3177
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
    Moeckel, Camille
    Bakhl, Katrina
    Georgakopoulos-Soares, Ilias
    Zaravinos, Apostolos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [32] Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).
    Agarwal, Archana
    Nassar, Amin
    Pond, Gregory Russell
    Barletta, Justine A.
    Acosta, Andres
    Abou Alaiwi, Sarah
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [33] Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer
    Liddell, Savannah S.
    Chakrabarti, Sakti
    Wintheiser, Grant A.
    Zemla, Tyler J.
    Shi, Qian
    Tella, Sri Harsha
    Jin, Zhaohui
    Wookey, Vanessa B.
    Hassan, Hind
    Tran, Nguyen H.
    Borad, Mitesh J.
    Mahipal, Amit
    JCO PRECISION ONCOLOGY, 2022, 6
  • [34] Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors
    Yu, James
    Park, Robin
    Miao, Ruoyu
    Imanirad, Iman
    Shahzad, Moazzam
    Laborde, Jose M.
    Knepper, Todd C.
    Walko, Christine M.
    Kim, Richard
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (09) : 378 - 383
  • [35] PROBABILISTIC MIXTURE MODELS IMPROVE CALIBRATION OF PANEL-DERIVED TUMOR MUTATIONAL BURDEN IN THE CONTEXT OF BOTH TUMOR-NORMAL AND TUMOR-ONLY SEQUENCING
    Anaya, Jordan
    Sidhom, John-William
    Baras, Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1319 - A1319
  • [36] Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population
    Scobie, Micaela R.
    Zhou, Katherine I.
    Ahmed, Sara
    Kelley, Michael J.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [37] Exploring tumor mutational burden status and clinical benefit of immune checkpoint inhibitors in endometrial cancer
    Valente, Ana
    Gin, Amy
    Wells, Allison
    Ding, Kai
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : E15 - E16
  • [38] Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).
    Wang, Daniel Ying
    Owen, Carina N.
    Palmieri, David James
    Cohen, Justine Vanessa
    Eroglu, Zeynep
    Long, Georgina V.
    Sullivan, Ryan J.
    Balko, Justin M.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Johnson, Douglas Buckner
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Kim, Jong Yeob
    Kronbichler, Andreas
    Eisenhut, Michael
    Hong, Sung Hwi
    van der Vliet, Hans J.
    Kang, Jeonghyun
    Shin, Jae Il
    Gamerith, Gabriele
    CANCERS, 2019, 11 (11)
  • [40] Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing
    Anaya, Jordan
    Sidhom, John -William
    Cummings, Craig A.
    Baras, Alexander S.
    AACR Project GENIE Consortium
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (03): : 501 - 509
12345